Comparative Pharmacology
Head-to-head clinical analysis: ACYCLOVIR versus XERESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYCLOVIR versus XERESE.
ACYCLOVIR vs XERESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
XERESE is a fixed-dose combination of clobetasol propionate (a corticosteroid) and acitretin (a retinoid). Clobetasol propionate binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines and reduce inflammation. Acitretin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating keratinocyte proliferation and differentiation.
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
One vaginal tablet (100 mg clindamycin + 200 mg clotrimazole) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateAcyclovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Acyclovir."
Clinical Note
moderateTizanidine + Acyclovir
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Terminal half-life is approximately 8.5 hours (6–11 h) in healthy adults, supporting twice-daily dosing.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Renal: ~51% as unchanged drug; fecal: ~33% (partially as metabolites).
Category A/B
Category C
Antiviral
Antiviral